Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Synlait Milk Ltd. ( (AU:SM1) ) just unveiled an announcement.
Synlait Milk Limited announced its financial results for the fiscal year ending July 31, 2025, and revealed a binding agreement to sell its North Island assets to Abbott, a global healthcare leader. This sale, valued at approximately NZ$307 million, is aimed at reducing Synlait’s debt and strengthening its financial position. The transaction is expected to complete by April 2026, subject to regulatory approvals. The sale is seen as a strategic move to streamline operations and explore diversification opportunities. The company’s FY25 results showed a significant improvement, with a net profit after tax of $0.8 million, a reduction in net debt, and increased profits in several business units, indicating a positive turnaround from previous challenges.
The most recent analyst rating on (AU:SM1) stock is a Sell with a A$0.58 price target. To see the full list of analyst forecasts on Synlait Milk Ltd. stock, see the AU:SM1 Stock Forecast page.
More about Synlait Milk Ltd.
Synlait Milk Limited is a company in the dairy industry, primarily focusing on the production and sale of milk and related products. It operates in the New Zealand market and has a significant focus on exporting its products to international markets.
Average Trading Volume: 23,928
Technical Sentiment Signal: Hold
Current Market Cap: A$372.4M
For an in-depth examination of SM1 stock, go to TipRanks’ Overview page.